SG Americas Securities LLC Invests $146,000 in REGENXBIO Inc. (NASDAQ:RGNX)

SG Americas Securities LLC purchased a new stake in shares of REGENXBIO Inc. (NASDAQ:RGNX) during the third quarter, HoldingsChannel reports. The institutional investor purchased 13,945 shares of the biotechnology company’s stock, valued at approximately $146,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. boosted its stake in REGENXBIO by 80.3% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 170,218 shares of the biotechnology company’s stock valued at $3,586,000 after purchasing an additional 75,800 shares during the last quarter. Integral Health Asset Management LLC lifted its holdings in shares of REGENXBIO by 25.0% during the second quarter. Integral Health Asset Management LLC now owns 950,000 shares of the biotechnology company’s stock valued at $11,115,000 after purchasing an additional 190,000 shares in the last quarter. Quest Partners LLC boosted its position in shares of REGENXBIO by 11,731.0% during the second quarter. Quest Partners LLC now owns 42,000 shares of the biotechnology company’s stock valued at $491,000 after buying an additional 41,645 shares during the last quarter. ProShare Advisors LLC increased its holdings in REGENXBIO by 8.3% in the 1st quarter. ProShare Advisors LLC now owns 11,384 shares of the biotechnology company’s stock worth $240,000 after buying an additional 874 shares in the last quarter. Finally, Squarepoint Ops LLC increased its holdings in REGENXBIO by 630.9% in the 2nd quarter. Squarepoint Ops LLC now owns 146,259 shares of the biotechnology company’s stock worth $1,711,000 after buying an additional 126,249 shares in the last quarter. Institutional investors own 88.08% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have issued reports on RGNX. Barclays lowered their target price on shares of REGENXBIO from $55.00 to $50.00 and set an “overweight” rating on the stock in a research note on Monday, August 5th. Chardan Capital restated a “buy” rating and set a $52.00 price objective on shares of REGENXBIO in a research report on Tuesday. StockNews.com raised shares of REGENXBIO from a “sell” rating to a “hold” rating in a research report on Friday, September 20th. HC Wainwright reiterated a “buy” rating and set a $39.00 target price on shares of REGENXBIO in a research note on Wednesday, September 4th. Finally, Raymond James restated an “outperform” rating and issued a $18.00 price target on shares of REGENXBIO in a research note on Thursday, October 10th. Three analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $35.45.

Insider Buying and Selling at REGENXBIO

In other news, CEO Curran Simpson sold 9,648 shares of the stock in a transaction on Monday, July 29th. The shares were sold at an average price of $15.04, for a total value of $145,105.92. Following the completion of the sale, the chief executive officer now directly owns 170,137 shares of the company’s stock, valued at $2,558,860.48. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, CEO Curran Simpson sold 9,648 shares of REGENXBIO stock in a transaction on Monday, July 29th. The shares were sold at an average price of $15.04, for a total transaction of $145,105.92. Following the transaction, the chief executive officer now owns 170,137 shares in the company, valued at approximately $2,558,860.48. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Argeris N. Karabelas sold 10,100 shares of the stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $13.51, for a total value of $136,451.00. Following the completion of the sale, the director now owns 11,286 shares of the company’s stock, valued at $152,473.86. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 50,848 shares of company stock valued at $665,197 over the last 90 days. 13.13% of the stock is currently owned by corporate insiders.

REGENXBIO Stock Performance

NASDAQ RGNX opened at $9.35 on Friday. The business’s fifty day moving average is $11.10 and its 200 day moving average is $13.05. REGENXBIO Inc. has a fifty-two week low of $9.11 and a fifty-two week high of $28.80. The company has a market capitalization of $460.54 million, a PE ratio of -1.59 and a beta of 1.21.

REGENXBIO (NASDAQ:RGNX) last posted its quarterly earnings data on Thursday, August 1st. The biotechnology company reported ($1.05) EPS for the quarter, topping the consensus estimate of ($1.29) by $0.24. The firm had revenue of $22.30 million for the quarter, compared to the consensus estimate of $22.97 million. REGENXBIO had a negative return on equity of 68.21% and a negative net margin of 270.74%. The business’s revenue for the quarter was up 11.6% compared to the same quarter last year. During the same quarter last year, the company earned ($1.66) earnings per share. On average, sell-side analysts forecast that REGENXBIO Inc. will post -4.66 EPS for the current year.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.